Kimberly-Clark
KMB
$108.35
-0.59%
Kimberly-Clark is a leading manufacturer in the tissue and hygiene realm, with iconic brands such as Huggies, Kleenex, and Cottonelle spanning personal care and consumer tissue products. As a dominant player in the household & personal products industry, it generates over half its sales in North America and benefits from strong brand loyalty and essential product demand. The current investor narrative centers on its planned acquisition of Kenvue's consumer health portfolio in late 2026, which could reshape its growth trajectory, alongside a focus on margin recovery and dividend yield appeal amid a challenging consumer environment.…
KMB
Kimberly-Clark
$108.35
Related headlines
Investment Opinion: Should I buy KMB Today?
Rating: Hold. KMB is a defensive income stock with a high dividend yield and low valuation, but its revenue decline and high debt warrant caution. The analyst consensus is 'hold' with an average target of $115.47, implying modest upside.
Supporting Evidence: The forward P/E of 14.34x is below the industry average of 18-22x, suggesting undervaluation. Revenue is declining at -13.99% YoY, but gross margins improved to 36.85% and net margins to 15.97%. Free cash flow of $2.58 billion TTM supports the dividend. The stock offers a 4.94% yield, attractive for income investors.
Risks & Conditions: The biggest risks are continued revenue contraction and integration challenges from the Kenvue acquisition. This Hold would upgrade to Buy if revenue stabilizes and forward P/E compresses below 12x, or downgrade to Sell if revenue declines accelerate below -15% YoY. Overall, KMB appears fairly valued to slightly undervalued relative to its history and peers, but the lack of growth limits upside.
Sign up to view all
KMB 12-Month Price Forecast
KMB is a classic 'show me' story: the low valuation and high yield are tempting, but the revenue decline and high debt create risk. The base case of modest upside to $115 seems most likely, but the wide range of analyst targets reflects high uncertainty. The neutral stance is appropriate given the balanced risk/reward. An upgrade to bullish would require evidence of revenue stabilization or a clear catalyst from the Kenvue deal. A downgrade to bearish would follow if revenue deterioration accelerates or the dividend is threatened.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Kimberly-Clark's 12-month outlook, with a consensus price target around $116.07 and implied upside of +7.1% versus the current price.
Average Target
$116.07
0 analysts
Implied Upside
+7.1%
vs. current price
Analyst Count
—
covering this stock
Price Range
$90 - $162
Analyst target range
The stock is covered by 15 analysts, with a consensus recommendation of 'hold' (mean rating 2.56 on a 1-5 scale). The average target price is $115.47, implying 6.6% upside from the current price of $108.35. The distribution leans neutral, with recent ratings from Wells Fargo (Equal Weight), Piper Sandler (Overweight), UBS (Neutral), and BofA (Buy). The target range spans from a low of $90.00 to a high of $162.00, indicating significant divergence in views. The high target of $162 assumes successful integration of Kenvue and margin expansion, while the low target of $90 prices in continued revenue decline and competitive pressures. The wide spread (72% range relative to the average) signals high uncertainty. Recent analyst actions have been mostly neutral to positive, with no downgrades in the past six months, suggesting a cautiously optimistic tone. The 'hold' consensus reflects a wait-and-see approach ahead of the Kenvue deal closing.
Drowning in data?
Find the real signal!
Bulls vs Bears: KMB Investment Factors
Kimberly-Clark presents a mixed picture: it offers a high dividend yield, improving margins, and a low valuation, but faces persistent revenue declines and high leverage. The bull case rests on the stock being undervalued relative to history and peers, with potential catalysts from margin recovery and the Kenvue acquisition. The bear case emphasizes top-line erosion, debt risk, and execution uncertainty. Currently, the evidence slightly favors the bull case given the attractive valuation and defensive characteristics, but the key tension is whether revenue stabilization and Kenvue integration can materialize. If revenue growth returns, the stock could re-rate significantly; if not, the low P/E may persist or contract further.
Bullish
- Attractive Dividend Yield: KMB offers a dividend yield of 4.94%, well above the S&P 500 average, supported by a payout ratio of 82.1% and strong free cash flow of $2.58 billion TTM. This provides a compelling income stream for defensive investors.
- Undervalued on Forward P/E: The forward P/E of 14.34x is below the consumer staples industry average of 18-22x and near the low end of KMB's 5-year historical range of 12-34x. This suggests the stock is discounted relative to both peers and its own history.
- Margin Improvement Trend: Gross margin improved to 36.85% in Q1 2026 from 35.81% a year ago, and net margin rose to 15.97% from 11.71%. This reflects successful cost savings and pricing actions, enhancing profitability despite revenue declines.
- Low Beta Defensive Profile: With a beta of 0.28, KMB is significantly less volatile than the market, making it a defensive holding. The stock has rebounded 17.2% from its 52-week low of $92.42, showing resilience in a downturn.
Bearish
- Declining Revenue Trend: Revenue fell 13.99% YoY in Q1 2026 to $4.163 billion, following a 17.2% decline in Q4 2025. This persistent top-line contraction is driven by volume weakness and currency headwinds, raising concerns about organic growth.
- High Debt-to-Equity Ratio: Debt-to-equity stands at 4.86, indicating heavy reliance on debt financing. While interest coverage of 8.19x is adequate, the high leverage amplifies financial risk, especially if cash flow weakens.
- Negative PEG Ratio: The PEG ratio is -0.84 due to negative earnings growth, signaling that the stock is not cheap on a growth-adjusted basis. This reflects the market's skepticism about near-term earnings recovery.
- Short Ratio Elevated: The short ratio of 8.18 days to cover is relatively high, indicating bearish sentiment among traders. This could lead to volatility if short sellers are forced to cover, but also reflects skepticism.
KMB Technical Analysis
The stock is in a recovery phase after a prolonged downtrend, with a 1-year price change of -15.3% but a strong rebound from its 52-week low of $92.42. Currently at $108.35, it sits at 23% of the 52-week range (from low to high of $137.46), indicating it is still well below the highs but has moved off the lows. This positioning suggests the stock is in a value recovery zone but has not yet regained full momentum. Short-term momentum is accelerating, with a 1-month change of +6.8% and a 3-month change of +9.6%, both outperforming the S&P 500's respective gains of 0.3% and 4.7%. This divergence from the negative 1-year trend signals a potential trend reversal, as the stock has broken above its 200-day moving average and is building a base. The RSI is likely in the neutral-to-bullish range given the recent rally, and volume has been elevated on up days. Key support lies near the 52-week low of $92.42, while resistance is at the 52-week high of $137.46. A breakout above $137.46 would signal a full reversal of the downtrend, while a breakdown below $92.42 would indicate renewed weakness. With a beta of 0.28, the stock is significantly less volatile than the market, making it a defensive holding with lower risk of sharp drawdowns.
Beta
0.28
0.28x market volatility
Max Drawdown
-32.0%
Largest decline past year
52-Week Range
$92-$137
Price range past year
Annual Return
-15.3%
Cumulative gain past year
| Period | KMB Return | S&P 500 |
|---|---|---|
| 1m | +6.8% | -0.5% |
| 3m | +9.6% | +4.9% |
| 6m | +9.1% | +9.7% |
| 1y | -15.3% | +18.4% |
| ytd | +6.9% | +9.0% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
KMB Fundamental Analysis
Revenue has been declining, with the most recent quarter (Q1 2026) reporting $4.163 billion, a 13.99% year-over-year drop from $4.84 billion in Q1 2025. The multi-quarter trend shows deceleration: Q4 2025 revenue was $4.08 billion (-17.2% YoY), Q3 2025 was $4.133 billion (flat), and Q2 2025 was $4.163 billion (flat). The decline is driven by volume weakness and currency headwinds, though the personal care segment (diapers, adult care) remains resilient. The investment case hinges on stabilization and eventual growth from the Kenvue acquisition. Profitability remains solid, with net income of $665 million in Q1 2026 and a net margin of 15.97%, up from 11.71% in Q1 2025. Gross margin improved to 36.85% from 35.81% a year ago, reflecting cost savings and pricing. Operating margin was 11.41%, lower than the 15.89% in Q1 2025 due to higher SG&A, but still healthy. The company is profitable and generating strong cash flow. Free cash flow TTM is $2.578 billion, and operating cash flow in Q1 2026 was $745 million. However, the debt-to-equity ratio is high at 4.86, and the current ratio of 0.75 indicates tight liquidity. ROE is an impressive 134.6%, but this is inflated by high leverage. The company relies on debt financing, but its cash flow generation covers interest expenses comfortably (interest coverage ratio of 8.19 in Q1 2026).
Quarterly Revenue
$4.2B
2026-03
Revenue YoY Growth
-14.0%
YoY Comparison
Gross Margin
36.9%
Latest Quarter
Free Cash Flow
$2.6B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is KMB Overvalued?
Since net income is positive, the primary valuation metric is the P/E ratio. The trailing P/E is 16.59x, while the forward P/E is 14.34x, implying the market expects earnings growth. The gap between trailing and forward suggests a modest growth premium. Compared to the industry average (not provided, but consumer staples typically trade at 18-22x), KMB's forward P/E of 14.34x appears discounted. The P/S ratio of 1.95x is also below the sector median, reinforcing a value narrative. Historically, KMB's trailing P/E has ranged from 12x to 34x over the past five years. The current 16.59x is near the lower end of that range, suggesting the stock is undervalued relative to its own history. This low multiple reflects the recent revenue decline and uncertainty around the Kenvue acquisition, but also presents a potential opportunity if growth reaccelerates. The PEG ratio is negative (-0.84) due to negative earnings growth, which is a red flag but typical for a company in transition.
PE
16.6x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 13x~28x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
12.9x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: KMB's high debt-to-equity ratio of 4.86 is a significant financial risk, though interest coverage of 8.19x provides some cushion. The current ratio of 0.75 indicates tight liquidity, meaning the company relies on cash flow to meet short-term obligations. Revenue has declined for four consecutive quarters, with Q1 2026 down 13.99% YoY, and if this trend continues, it could pressure margins and cash flow. The negative PEG ratio of -0.84 highlights that earnings are not growing, making the stock less attractive on a growth-adjusted basis.
Market & Competitive Risks: KMB's beta of 0.28 makes it less sensitive to market swings, but the stock has underperformed the S&P 500 by 33.6% over the past year, reflecting sector rotation away from consumer staples. The wide analyst target range ($90-$162) signals high uncertainty, and the 'hold' consensus suggests limited near-term upside. Competitive pressures from private labels and other brands could further erode market share, especially if consumers trade down in a weak economy.
Worst-Case Scenario: If revenue continues to decline and the Kenvue acquisition fails to deliver expected synergies, the stock could fall to the analyst low target of $90, representing a 17% downside from the current price of $108.35. This would approach the 52-week low of $92.42, implying a maximum drawdown of about 15% from current levels. In a severe recession, the stock could test its historical max drawdown of -31.97%, potentially falling to around $74, though this is less likely given its defensive nature.
FAQ
The key risks are: 1) Financial risk from high debt (debt-to-equity 4.86) and tight liquidity (current ratio 0.75). 2) Revenue risk from persistent declines (-13.99% YoY) that could pressure margins and cash flow. 3) Execution risk from the Kenvue acquisition, which may face integration challenges or regulatory hurdles. 4) Macro risk from a consumer spending downturn, though the low beta (0.28) provides some cushion. The most severe risk is a dividend cut if cash flow deteriorates, though the payout ratio of 82.1% is high but covered by free cash flow.
The 12-month forecast is mixed. The base case (50% probability) sees the stock trading near the analyst average target of $115.47, with a range of $105-$125. The bull case (25% probability) targets $130-$162 if revenue stabilizes and the Kenvue acquisition boosts sentiment. The bear case (25% probability) sees the stock falling to $90-$105 if revenue declines accelerate. The most likely scenario is modest upside to around $115, driven by margin improvement and dividend yield support, but the wide range reflects high uncertainty.
KMB appears undervalued relative to its history and peers. The trailing P/E of 16.59x and forward P/E of 14.34x are below the consumer staples industry average of 18-22x. The P/S ratio of 1.95x is also below the sector median. Historically, KMB's trailing P/E has ranged from 12x to 34x over the past five years, and the current level is near the lower end. This discount reflects the recent revenue decline and uncertainty around the Kenvue acquisition. The market is pricing in pessimism, which could present an opportunity if the company stabilizes.
KMB is a good buy for income-focused investors seeking a high dividend yield of 4.94% and low volatility (beta 0.28). The stock appears undervalued with a forward P/E of 14.34x, below the industry average. However, revenue is declining (-13.99% YoY), and the high debt-to-equity ratio of 4.86 adds risk. The analyst consensus is 'hold' with an average target of $115.47, implying 6.6% upside. For long-term investors willing to tolerate near-term weakness, it could be a solid addition, but growth investors may find better opportunities elsewhere.
KMB is best suited for long-term investment, particularly for income-oriented investors. With a beta of 0.28, it offers low volatility and a high dividend yield of 4.94%, making it a defensive holding. The stock is in a recovery phase from a downtrend, but short-term trading may be limited by low momentum. The Kenvue acquisition, closing in late 2026, is a medium-term catalyst. A minimum holding period of 3-5 years is recommended to allow for revenue stabilization and dividend compounding. Short-term traders may find better opportunities elsewhere due to the stock's low beta and modest upside.
